Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate

David Hosking; Kenneth Lyles; Jacques P Brown; William D Fraser; Paul Miller; Manuel Diaz Curiel; Jean-Pierre Devogelaer; Michael Hooper; Guoqin Su; Ken Zelenakas; Judy Pak; Taiwo Fashola; Youssef Saidi; Erik Fink Eriksen; Ian R Reid

doi:10.1359/jbmr.061001

Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate

David Hosking, Kenneth Lyles, Jacques P Brown, William D Fraser, Paul Miller, Manuel Diaz Curiel, Jean-Pierre Devogelaer, Michael Hooper, Guoqin Su, Ken Zelenakas, Judy Pak, Taiwo Fashola, Youssef Saidi, Erik Fink Eriksen, Ian R Reid

Research output: Contribution to journal › Article › peer-review

135 Citations (Scopus)

Abstract

A single 5-mg infusion of zoledronic acid restores biochemical markers of bone turnover into the reference range in the majority of patients with Paget's disease and maintains biochemical remission for at least 2 years. This effect is largely independent of pretreatment disease activity and prior bisphosphonate therapy.

Original language	English
Pages (from-to)	142-148
Number of pages	7
Journal	Journal of Bone and Mineral Research
Volume	22
Issue number	1
DOIs	https://doi.org/10.1359/jbmr.061001
Publication status	Published - Jan 2007

Keywords

Administration, Oral
Aged
Aged, 80 and over
Alkaline Phosphatase
Bone Density Conservation Agents
Bone and Bones
Diphosphonates
Etidronic Acid
Follow-Up Studies
Humans
Imidazoles
Infusions, Intravenous
Osteitis Deformans

Access to Document

10.1359/jbmr.061001

Cite this

Hosking, D., Lyles, K., Brown, J. P., Fraser, W. D., Miller, P., Curiel, M. D., Devogelaer, J-P., Hooper, M., Su, G., Zelenakas, K., Pak, J., Fashola, T., Saidi, Y., Eriksen, E. F., & Reid, I. R. (2007). Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. Journal of Bone and Mineral Research, 22(1), 142-148. https://doi.org/10.1359/jbmr.061001

@article{85c6f4c0e4cf4d48ac3e95788002d685,

title = "Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate",

abstract = "A single 5-mg infusion of zoledronic acid restores biochemical markers of bone turnover into the reference range in the majority of patients with Paget's disease and maintains biochemical remission for at least 2 years. This effect is largely independent of pretreatment disease activity and prior bisphosphonate therapy.",

keywords = "Administration, Oral, Aged, Aged, 80 and over, Alkaline Phosphatase, Bone Density Conservation Agents, Bone and Bones, Diphosphonates, Etidronic Acid, Follow-Up Studies, Humans, Imidazoles, Infusions, Intravenous, Osteitis Deformans",

author = "David Hosking and Kenneth Lyles and Brown, {Jacques P} and Fraser, {William D} and Paul Miller and Curiel, {Manuel Diaz} and Jean-Pierre Devogelaer and Michael Hooper and Guoqin Su and Ken Zelenakas and Judy Pak and Taiwo Fashola and Youssef Saidi and Eriksen, {Erik Fink} and Reid, {Ian R}",

year = "2007",

month = jan,

doi = "10.1359/jbmr.061001",

language = "English",

volume = "22",

pages = "142--148",

journal = "Journal of Bone and Mineral Research",

issn = "0884-0431",

publisher = "Wiley",

number = "1",

}

Hosking, D, Lyles, K, Brown, JP, Fraser, WD, Miller, P, Curiel, MD, Devogelaer, J-P, Hooper, M, Su, G, Zelenakas, K, Pak, J, Fashola, T, Saidi, Y, Eriksen, EF & Reid, IR 2007, 'Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate', Journal of Bone and Mineral Research, vol. 22, no. 1, pp. 142-148. https://doi.org/10.1359/jbmr.061001

TY - JOUR

T1 - Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate

AU - Hosking, David

AU - Lyles, Kenneth

AU - Brown, Jacques P

AU - Fraser, William D

AU - Miller, Paul

AU - Curiel, Manuel Diaz

AU - Devogelaer, Jean-Pierre

AU - Hooper, Michael

AU - Su, Guoqin

AU - Zelenakas, Ken

AU - Pak, Judy

AU - Fashola, Taiwo

AU - Saidi, Youssef

AU - Eriksen, Erik Fink

AU - Reid, Ian R

PY - 2007/1

Y1 - 2007/1

N2 - A single 5-mg infusion of zoledronic acid restores biochemical markers of bone turnover into the reference range in the majority of patients with Paget's disease and maintains biochemical remission for at least 2 years. This effect is largely independent of pretreatment disease activity and prior bisphosphonate therapy.

AB - A single 5-mg infusion of zoledronic acid restores biochemical markers of bone turnover into the reference range in the majority of patients with Paget's disease and maintains biochemical remission for at least 2 years. This effect is largely independent of pretreatment disease activity and prior bisphosphonate therapy.

KW - Administration, Oral

KW - Aged

KW - Aged, 80 and over

KW - Alkaline Phosphatase

KW - Bone Density Conservation Agents

KW - Bone and Bones

KW - Diphosphonates

KW - Etidronic Acid

KW - Follow-Up Studies

KW - Humans

KW - Imidazoles

KW - Infusions, Intravenous

KW - Osteitis Deformans

U2 - 10.1359/jbmr.061001

DO - 10.1359/jbmr.061001

M3 - Article

C2 - 17032148

VL - 22

SP - 142

EP - 148

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 1

ER -